Hong Kong-listed biopharmaceutical company RemeGen Co., Ltd. released its Monthly Return on Movements in Securities for August 2026, showing a largely unchanged share structure with a small repurchase of A shares for employee incentive purposes.

Authorised and Issued Capital • Authorised/registered capital remained steady at 564.48 million shares, split between 208.58 million H shares and 355.90 million A shares, each with a par value of RMB 1. • No new shares were authorised or issued during the month.

H-Share Position Unchanged, Public Float Intact • The company’s Hong Kong-listed H shares (208.58 million) recorded no movement in either issued or treasury shares. • RemeGen confirmed compliance with the Exchange’s 5 % minimum public-float requirement for PRC issuers.

A-Share Activity: Targeted Repurchase for Incentive Schemes • On 3 August 2026 the company repurchased 28,040 A shares on the Shanghai Stock Exchange at RMB 108.72 each, spending roughly RMB 3.05 million. • The repurchased shares were transferred to treasury, increasing the treasury stock balance to 235,184 A shares, while reducing outstanding A shares to 355.66 million. • The buyback is earmarked for future allocations under existing employee equity incentive plans.

Outstanding Restricted Share Pools • 2022 A-Share Incentive Scheme: up to 1.05 million shares remain available for future attribution (693,860 from the first grant and 360,440 from the reserved grant). • 2023 A-Share Incentive Scheme: 1.08 million shares remain available following previous lapses and attributions.

Net Result for August 2026 • Total issued share capital fell marginally by 28,040 A shares, reflecting the stated repurchase. • Treasury shares increased by the same amount, with no cancellations executed during the month.

The disclosure underscores RemeGen’s disciplined capital management, preserving overall share count stability while advancing employee incentive programs without affecting the public-float threshold on the Hong Kong Stock Exchange.